|
July. 31, 2020 |
|
|
Dec. 20, 2021 |
|
|
jRCT2080225296 |
- |
|
- |
Eli Lilly Japan K.K. |
||
- |
||
+81-120-023-812 |
||
- |
Eli Lilly Japan K.K. |
||
- |
||
+81-120-023-812 |
||
- |
recruiting |
Sept. 01, 2020 |
||
| 280 | ||
Interventional |
||
- |
||
treatment purpose |
||
2 |
||
- |
||
- |
||
| 18age old over | ||
| 65age old under | ||
Both |
||
- |
||
investigational material(s) |
||
efficacy |
||
efficacy |
||
| Eli Lilly Japan K.K. | |
| - |
| - | |
| - |
| - | |
| - | |
- |
|
| approved | |
July. 06, 2020 |
| NCT04433585 | |
| ClinicalTrials.gov |
| JapicCTI-205392 | |
| Japan/Asia except Japan/North America/South America/Europe/Oceania/- |